Screener
Discontinued — last reported Q4 '24
EBIT at other companies
Other financials
Where this comes from
Calculated from Summit Therapeutics’s reported figures.
The source filing: Summit Therapeutics’s 10-K, filed February 23, 2026. Open the filing →
- Filed
- Feb 23, 2026, 4:10 PM EST
- Fiscal year
- FY2025
- Accession
- 0001599298-26-000015
FAQ
- What is Summit Therapeutics's EBIT?
- Summit Therapeutics (SMMT) reported EBIT of -$65.61M in Q4 2024.
- How has Summit Therapeutics's EBIT changed year-over-year?
- Summit Therapeutics's EBIT decreased by 81.2% year-over-year, from -$36.21M to -$65.61M.
- What is the long-term trend for Summit Therapeutics's EBIT?
- Over 3 years (2021 to 2024), Summit Therapeutics's EBIT has grown at a 37.9% compound annual growth rate (CAGR), from -$86.19M to -$226M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about Summit Therapeutics's ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude